Voyager Therapeutics (VYGR) Total Liabilities (2014 - 2026)

Voyager Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $43.4 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 44.5% year-over-year to $43.4 million; the TTM figure through Jun 2026 stood at $43.4 million (down 44.5% YoY), while the FY2025 annual figure was $56.2 million, down 39.76% from the prior year.
• Total Liabilities came in at $43.4 million for Q2 2026 at Voyager Therapeutics, down from $45.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $148.3 million in Q1 2022 to a low of $43.4 million in Q2 2026.
• Average Total Liabilities over 5 years is $96.7 million, with a median of $100.6 million recorded in 2022.
• Year-over-year, Total Liabilities surged 46.05% in 2022 and plunged 44.5% in 2026.
• Over 5 years, Total Liabilities stood at $100.3 million in 2022, then climbed by 14.58% to $115.0 million in 2023, then fell by 18.85% to $93.3 million in 2024, then plunged by 39.76% to $56.2 million in 2025, then retreated by 22.82% to $43.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $43.4 million in Q2 2026, $45.7 million in Q1 2026, and $56.2 million in Q4 2025.